[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obesity-in-children\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obesity-in-children":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100585558","phase-2-bone-metabolism-in-12-21-year-olds-undergoing-glucagon-like-peptide-glp-1-receptor-agonist-therapy-100585558",false,"NCT06903923","Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy","Bone Metabolism in Adolescents Undergoing GLP-1 Receptor Agonist Therapy","Inclusion Criteria:\n\n* • Adolescents and young adults with obesity 12-21 years old starting GLP-1 RA therapy (except for dulaglutide or exenatide) or followed with 'usual' care.\n* Diagnosis of obesity (BMI ≥ 95th percentile for age and sex). The FDA has approved the use of GLP-1 RAs (liraglutide and semaglutide) for adolescents ≥ 12 years old with BMI ≥ 95th percentile for age and sex, and tirzepatide for adults with obesity. Those in the GLP-1 RA arm must have demonstrated efforts at weight loss with 'usual' care, and consistent compliance with appointments and recommendations.\n* Participants must demonstrate sufficient maturity, psychological stability and cognitive capacity to recognize the significance of being on medical therapy and implement required behavioral changes\n* Patients taking orlistat as a precursor to GLP-1 RA therapy due to insurance requirements may be included given minimal effects on weight.\n* Use of the following contraceptive methods is permitted: Combine oral contraceptives (COCs); continuous oral progestin; Progestin-releasing intrauterine device (IUD); Progestin implant; transdermal patch.\n* Patients with celiac disease will be included if the condition is well controlled and they are on a gluten free diet with normal 25(OH)D levels confirmed by clinical labs within 3 months of enrollment in the study. If a patient does not have recent 25(OH)D results, we will add this to the screening labs.\n\nExclusion Criteria:\n\n* • Current or previous history of pregnancy and breast feeding.\n* Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 if in the GLP-1 RA group.\n* \\> 5 kg weight loss over 3 months given the known impact of significant weight loss on bone density.\n* Use of dulaglutide and exenatide (of the GLP-1 RAs) given minimal weight loss with these drugs.\n* Use of medications such as metformin, phentermine, or topiramate that may cause weight loss, or obesogenic antipsychotic medications if treated for \\\u003C3 months, or if dosage is not stable for \\>2 months.\n* Medications other than calcium or vitamin D that affect bone, such as systemic glucocorticoids, phenytoin, phenobarbitone (unless there is a washout period of 3 months prior to enrollment if discontinuation is medically permissible)\n* Female participants on hormonal contraception will be excluded if this involves use of depot medroxyprogesterone acetate (DMPA). DMPA has profound deleterious effect on bone density, which could confound study outcomes related to bone health. Rationale: DMPA has a well-documented deleterious effect on bone density, which could confound study outcomes related to bone health or metabolic parameters.\n* Untreated thyroid dysfunction or on stable dose for \\\u003C3 months. Primary thyroid dysfunction will be defined as: a TSH ≥ 10 IU\u002FL or low per given reference range with unknown thyroid antibody status, or an abnormal TSH if known positive antibodies. Patients with known hypothyroidism will be included if appropriately treated with levothyroxine and have a normal TSH. For patients with secondary hypothyroidism (deficient production of TSH from the pituitary gland causing hypothyroidism), normal free T4 concentrations (and not TSH alterations) will be used for study inclusion, and recent adjustments in the levothyroxine dose will be permissible as long as free T4 concentrations are in the normal range at dose adjustment (as dose adjustments are often made to get free T4 concentrations in the upper half of the normal range when assessed levels are in the lower half of the normal range). Patients with hyperthyroidism will be excluded given known deleterious effects on both weight and bone metabolism.\n* Medical conditions known to impact weight or bone density, such as chronic gastrointestinal disorders (including inflammatory bowel disease), other inflammatory conditions, such as rheumatoid arthritis or ankylosing spondylitis, untreated thyroid disease, and hypercortisolemia.\n* HbA1C \\>8% (to avoid deleterious effects on bone from uncontrolled T2DM).\n* Smoking \\>10 cigarettes\u002Fday given deleterious effects on bone; substance abuse per DSM-5.\n* Weight \\>450 lbs due to limits for DXA scanners.\n* History of metabolic and bariatric surgery.\n* Judged by the investigators to be inappropriate for the study for other reasons not detailed above.","ALL","12 Years","21 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to compare bone health markers over 24 months in participants 12 - 21 years of age with obesity who are starting the glucagon-like peptide-1 receptor agonists (GLP-1RAs) as compared to those with similar weight followed by lifestyle management.\n\nParticipants will:\n\n* Take GLP-1RA as prescribed or continue to work on lifestyle management for weight loss\n* Take provided calcium and vitamin D supplements\n* Attend 6 study visits over 24 months with two at the beginning and then every 6 months that include:\n\n  * History and Physical Exams\n  * Lab Work\n  * Imaging studies\n  * Questionnaires\n  * 24-hour dietary recalls",[27,28,29,30,31,32],"Obesity in Children","Bone Strength","GLP - 1","Lifestyle Modification","Bone Density","Obesity",[34,35,36,37,38,39,40,41],"obesity","obesity in children","bone strength","GLP-1","Lifestyle modification","bone density","semaglutide","liraglutide","RECRUITING","2026-04-15",{"date":45,"type":46},"2026-04-17","ACTUAL",{"date":48,"type":46},"2025-07-31",{"date":50,"type":21},"2030-04-30",{"name":52,"class":53},"University of Virginia","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":16,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":54},"100570296","the-bloom-study---a-safe-and-healthy-start-in-life-100570296","NCT06705400","The Bloom Study - a Safe and Healthy Start in Life","Inclusion Criteria:\n\nAll children born from first-time mothers being in gestation week 20 between November 1st 2024 and October 31st 2025.\n\nExclusion Criteria:\n\nNot being able to receive digital post.",true,"0 Months","6 Months",{"count":65,"type":21},3500,[67],"NA","The aim of the Bloom Study is to promote healthy weight development among infants through a home-based health promoting intervention implemented in the Danish setting of community health nurses. The intervention begins during pregnancy and runs until the child reaches the age of 30 months.\n\nThe Bloom Intervention was developed over a six-year period from 2017 to 2023 according to the Intervention Mapping approach and based on a co-creation process.\n\nThe Bloom Intervention is evaluated in a cluster-randomized trial involving 22 Danish municipalities (11 intervention and 11 control). All children born from first-time mothers over a period of 12 months are invited to participate.",[70,27],"Overweight, Childhood",[72,73,74,75,76,77,78,79,80,81,82,32,83,84,85,86],"The Bloom Study","Intervention","Infants","Weight status","Community health nurses","Home-based","Randomized controlled trial","Children","Multi-component","Health promotion and prevention","Overweight","Food habits and meals","Motor skills and movement","Screen use","Sleep","2025-12-15",{"date":89,"type":46},"2025-12-22",{"date":91,"type":46},"2024-11-01",{"date":93,"type":21},"2029-03-31",{"name":95,"class":53},"University of Southern Denmark",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":117,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":135},"100569316","overview-use-of-respiratory-support-at-home-in-children-100569316","NCT06692660","Overview: Use of Respiratory Support At Home in Children","An Overview of the Use of Respiratory Support At Home in Children - Patients and Families Point of View","ELIPSE","Inclusion Criteria:\n\n* Children with respiratory support at home\n* Age 0 to 18 (not yet passed) years old\n\nExclusion Criteria:\n\n* Palliative care\n* Invasive ventilation\n* High flow oxygen therapy","0 Years","17 Years",{"count":107,"type":21},30,"OBSERVATIONAL","the primary outcome is to describe the perceived success of the use of the respiratory support from the parent's point of view",[111,27,112,113,114,115,116],"Sleep Apnea Syndromes in Children","Bronchopulmonary Dysplasia (BPD)","Neuromuscular Disease","Storage Disease","Malformation","Alveolar Hypoventilation",[118,119,120,121,122,123,124],"respiratory suport","sleep apnea syndrome","CPAP","BiPAP","ventilation","alveolar hypoventilation","non invasive ventilation","NOT_YET_RECRUITING","2024-11-14",{"date":128,"type":46},"2024-11-18",{"date":130,"type":21},"2024-11",{"date":132,"type":21},"2025-08",{"name":134,"class":53},"University Hospital, Grenoble",2]